Intravenous Hemostats: Foundation, Targeting, and Controlled-Release

Bioconjug Chem. 2022 Dec 21;33(12):2269-2289. doi: 10.1021/acs.bioconjchem.2c00492. Epub 2022 Nov 20.

Abstract

Uncontrollable blood loss is the greatest cause of mortality in prehospital patients and the main source of disability and death in hospital care. Compared with external hemostats, intravenous hemostats are more appropriate for preventing and treating uncontrolled bleeding in vivo and large bleeding on the body surface. This Review initially establishes intravenous hemostats' response basis, including the coagulation mechanism, fibrinolytic pathway, and protein corona. Second, the study of advancement of intravenous hemostat targeting was expanded from two perspectives, cellular hemostatic agents and synthetic hemostatic agents. Meanwhile, after discussing the progress of controlled-release intravenous hemostats with platelets as the stimuli, this Review offers insight into the possibility of controlled-release intravenous hemostats with microenvironment as the stimuli, combining the studies of controlled-release targeted thrombolysis.

Publication types

  • Review
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Delayed-Action Preparations
  • Hemorrhage
  • Hemostatics* / therapeutic use
  • Humans

Substances

  • Delayed-Action Preparations
  • Hemostatics